U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07156058) titled 'MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer' on Sept. 13, 2023.
Brief Summary: This research aims to study the effect of postoperative adjuvant therapy with a MiniPDX drug sensitivity test for biliary tract cancer.
Study Start Date: Jan. 01, 2023
Study Type: INTERVENTIONAL
Condition:
Biliary Tract Cancer
Intervention:
OTHER: MiniPDX group
Personalized treatment for guided by mini-PDX. The MiniPDX test can provide drug sensitivity results in as little as 7 days. Drugs including but not limited to the following agents: capecitabine, gemcitabine + cis-platinum, gemcitabine + capecitabine, 5-FU + oxalipl...